Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The platelet-activating factor receptor (PAFR) is a G-protein coupled receptor (GPCR) that binds platelet-activating factor (PAF), a potent phospholipid mediator involved in numerous physiological and pathological processes. PAFR is present in both plasma and nuclear membranes of most cells within the vascular system and innate immune system, participating broadly in inflammatory responses as well as other physiological functions such as reproduction and pulmonary gas exchange. It is implicated in various diseases including inflammation, cancer, and stroke, making it a therapeutic target.
Agonists bind to PAFR, activating Gi/Gq/G12/13 proteins, leading to downstream signaling cascades including PI-calcium second messenger system activation, intracellular calcium mobilization, MAPK/NF-kB pathway activation, cAMP inhibition, and EGF-R transactivation. Antagonists block PAF binding, inhibiting these signaling events.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Platelet-Activating Factor Receptor (PAFR).